SEARCH

SEARCH BY CITATION

References

  • 1
    Hancock EEW (2005) Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect Dis 5, 209218.
  • 2
    Herman T (2007) Aminoglycoside antibiotics: old drugs and new therapeutic approaches. Cell Mol Life Sci 64, 18411852.
  • 3
    McCoy LS, Xie Y & Tor Y (2011) Antibiotics that target protein synthesis. Wiley Interdiscip Rev RNA 2, 209232.
  • 4
    Yonath A (2005) Antibiotics targeting ribosomes: resistance, selectivity, synergism and cellular regulation. Annu Rev Biochem 74, 649679.
  • 5
    Tenson T & Mankin A (2006) Antibiotics and the ribosome. Mol Microbiol 59, 16641677.
  • 6
    Macmaster R, Zelinskaya N, Savic M, Rankin CR & Conn GL (2010) Structural insights into the function of aminoglycoside-resistance A1408 16S rRNA methyltransferases from antibiotic-producing and human pathogenic bacteria. Nucleic Acids Res 38, 77917799.
  • 7
    Wilson DN, Schluenzen F, Harms JM, Starosta AL, Connell SR & Fucini P (2008) The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci USA 105, 1333913344.
  • 8
    Walter F, Vicens Q & Westhof E (1999) Aminoglycoside–RNA interactions. Curr Opin Chem Biol 3, 694704.
  • 9
    Been MD (2006) HDV ribozymes. Curr Top Microbiol Immunol 307, 4765.
  • 10
    Cochrane JC & Strobel SA (2008) Catalytic strategies of self-cleaving ribozymes. Acc Chem Res 41, 10271035.
  • 11
    Fedor MJ (2009) Comparative enzymology and structural biology of RNA self-cleavage. Annu Rev Biophys 38, 271299.
  • 12
    Ferre-D'Amaro F, Zhou K & Doudna J (1998) Crystal structure of hepatitis delta virus ribozyme. Nature 395, 567574.
  • 13
    Ke A, Zhou K, Ding F, Cate JH & Doudna JA (2004) A conformational switch controls hepatitis delta virus ribozyme catalysis. Nature 429, 201205.
  • 14
    Chen JH, Yajima R, Chadalavada DM, Chase E, Bevilacqua PC & Golden BL (2010) A 1.9 A crystal structure of the HDV ribozyme precleavage suggests both Lewis acid and general acid mechanisms contribute to phosphodiester cleavage. Biochemistry 49, 65086518.
  • 15
    Golden BL (2011) Two distinct catalytic strategies in the hepatitis δ virus ribozyme cleavage reaction. Biochemistry 50, 94249433.
  • 16
    Deigan KE & Ferré-D'Amaré AR (2011) Riboswitches: discovery of drugs that target bacterial gene-regulatory RNAs. Acc Chem Res 44, 13291338.
  • 17
    Tor Y (2003) Targeting RNA with small molecules. ChemBioChem 4, 9981007.
  • 18
    Feig AL & Uhlenbeck OC (1999) The role of metal ions in RNA biochemistry. In RNA World (Gesteland RF, Cech TR & Atkins G, eds), pp. 287319. Cold Spring Harbour Laboratory Press, Plainview, NY.
  • 19
    Banci L, Bertini I, Cavallaro G & Ciofi-Baffoni S (2011) Seeking the determinants of the elusive functions of Sco proteins. FEBS J 278, 22442262.
  • 20
    Linder MC (1991) Biochemistry of Copper. Plenum Press, New York.
  • 21
    Siddiqui I, Farooqi JQ, Shariff DA, Khan AH & Ghani F (2006) Serum copper levels in various diseases: a local experience at Aga Khan University Hospital, Karachi. Int J Pathol 4, 101104.
  • 22
    Ferrigno D, Buccheri G & Camilla T (1999) Monaldi Arch Chest Dis 54, 204208.
  • 23
    Iwamoto T, Kagawa Y & Kojima M (2003) Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull 26, 876879.
  • 24
    Aboul-ela F (2010) Strategies for the design of RNA-binding small molecules. Future Med Chem 2, 93119.
  • 25
    Szafraniec M, Stokowa-Sołtys K, Nagaj J, Kasprowicz A, Wrzesinski J, Jeżowska-Bojczuk M & Ciesiołka J (2012) Capreomycin and hygromycin B modulate catalytic activity of the delta ribozyme in the manner that depends on these antibiotics' protonation and complexation with Cu(II) ions. Dalton Trans 41, 97289736.
  • 26
    Jeżowska-Bojczuk M & Bal W (1998) Coordination of copper(II) by amikacin. Complexation equilibria in solution and oxygen activation by the resulting complexes. J Chem Soc, Dalton Trans 1998, 153160.
  • 27
    Szczepanik W, Kaczmarek P & Jeżowska-Bojczuk M (2004) Identification of copper(II) binding sites in actinomycin D, a cytostatic drug – correlation of coordination with DNA damage. J Inorg Biochem 98, 21412148.
  • 28
    Jeżowska-Bojczuk M, Szczepanik W, Mangani S, Gaggelli E, Gaggelli N & Valensin G (2005) Identification of copper(II) binding sites in the aminoglycosidic antibiotic neomycin B. Eur J Inorg Chem 15, 30633071.
  • 29
    Wrzesinski J, Brzezowska M, Szczepanik W, Jezowska-Bojczuk M & Ciesiołka J (2006) Inhibition of the catalytic activity of trans-acting antigenomic delta ribozyme by selected antibiotics and their Cu2+ complexes. Biochem Biophys Res Commun 349, 13941400.
  • 30
    Rogers J, Chang AH, von Ahsen U, Schroeder R & Davies J (1996) Inhibition of the self-cleavage reaction of the human hepatitis delta virus ribozyme by antibiotics. J Mol Biol 259, 916925.
  • 31
    Weeks KM (2010) Advances in RNA structure analysis by chemical probing. Curr Opin Struct Biol 20, 295304.
  • 32
    Wrzesinski J & Ciesiołka J (2007) Characterization of structure and metal ion specificity of Co2+ -binding RNA aptamers. Biochemistry 44, 62576268.
  • 33
    Dutkiewicz M & Ciesiołka J (2005) Structural characterization of the highly conserved 98-base sequence at the 3′ end of HCV RNA genome and the complementary sequence located at the 5′ end of the replicative viral strand. Nucleic Acids Res 33, 693703.
  • 34
    Matysiak M, Wrzesiński J & Ciesiołka J (1999) Sequential folding of the genomic ribozyme of the hepatitis delta virus: structural analysis of RNA transcription intermediates. J Mol Biol 291, 294283
  • 35
    Merino EJ, Wilkinson KA, Coughlan JL & Weeks KM (2005) RNA structure analysis at single nucleotide resolution by selective 2′-hydroxyl acylation and primer extension (SHAPE). J Am Chem Soc 127, 42234231.
  • 36
    Wilkinson KA, Merino EJ & Weeks KM (2006) Selective 2′-hydroxyl acylation analyzed by primer extension (SHAPE): quantitative RNA structure analysis at single nucleotide resolution. Nat Protoc 1, 16101616.
  • 37
    McGinnis JL, Dunkle JA, Cate JH & Weeks KM (2012) The mechanisms of RNA SHAPE chemistry. J Am Chem Soc 134, 66176624.
  • 38
    Watts JM, Dang KK, Gorelick RJ, Leonard CW, Bess JW Jr, Swanstrom R, Burch CL & Weeks KM (2009) Architecture and secondary structure of an entire HIV-1 RNA genome. Nature 460, 711716.
  • 39
    Błaszczyk L & Ciesiołka J (2011) Secondary structure and the role in translation initiation of the 5′-terminal region of p53 mRNA. Biochemistry 50, 70807092.
  • 40
    Wrzesinski J, Łęgiewicz M, Smólska B & Ciesiołka J (2001) Catalytic cleavage of cis- and trans-acting antigenomic delta ribozymes in the presence of various divalent metal ions. Nucleic Acids Res 29, 44824492.
  • 41
    Łęgiewicz M, Wichłacz A, Brzezicha B & Ciesiołka J (2006) Antigenomic delta ribozyme variants with mutations in the catalytic core obtained by the in vitro selection method. Nucleic Acids Res 34, 12701280.
  • 42
    Wrzesinski J, Wichłacz A, Nijakowska D, Rebowska B, Nawrot B & Ciesiołka J (2010) Phosphate residues of antigenomic HDV ribozyme important for catalysis that are revealed by phosphorothioate modification. New J Chem 34, 10181026.
  • 43
    Zeidler J, Nijakowska D & Wrzesinski J (2012) Regulation of the antigenomic delta ribozyme catalytic activity by complexes of triazole derivatives with transition metal ions in a pH-dependent manner. Inorg Chem Commun 20, 330333.
  • 44
    Wrońska M, Wrzesinski J, Jeżowska-Bojczuk M, Szczepanik W, Starosta R, Barys M, Ciunik Z & Ciesiołka J (2012) The impact of isomers of hemiaminal-1,2,4-triazole conjugates differently substituted in the phenyl ring and their Cu2+ complexes on the catalytic activity of the antigenomic delta ribozyme. J Inorg Chem 108, 6268.
  • 45
    Kamitori S & Takusagawa F (1992) Crystal structure of the 2:1 complex between d(GAAGCTTC) and the anticancer drug actinomycin D. J Mol Biol 225, 445456.
  • 46
    Veeraraghavan N, Ganguly A, Chen JH, Bevilacqua PC, Hammes-Schiffer S & Golden BL (2011) Metal binding motif in the active site of the HDV ribozyme binds divalent and monovalent ions. Biochemistry 50, 26722682.
  • 47
    Lee T-S, Giambasu GM, Harris ME & York DM (2011) Characterization of the structure and dynamics of the HDV ribozyme at different stages along the reaction path. J Phys Chem Lett 2, 25382543.
  • 48
    Veeraraghavan N, Ganguly A, Golden BL, Bevilacqua PC & Hammes-Schiffer S (2011) Mechanistic strategies in the HDV ribozyme: chelated and diffuse metal ion interactions and active site protonation. J Phys Chem B 115, 83468357.
  • 49
    Brooks BR, Brooks CL 3rd, Mackerell AD Jr, Nilsson L, Petrella RJ, Roux B, Won Y, Archontis G, Bartels C, Boresch S et al. (2009) CHARMM: the biomolecular simulation program. J Comput Chem 30, 15451614.
  • 50
    MacKerell AD Jr, Banavali N & Foloppe N (2000) Development and current status of the CHARMM force field for nucleic acids. Biopolymers 56, 257265.